PMC:4134656 / 16762-17802 JSONTXT

{"project":"2_test","denotations":[{"id":"25136206-21788220-58659572","span":{"begin":441,"end":443},"obj":"21788220"},{"id":"25136206-23278381-58659573","span":{"begin":848,"end":850},"obj":"23278381"},{"id":"25136206-23405852-58659574","span":{"begin":1037,"end":1039},"obj":"23405852"}],"text":"The duration of therapy depends on the morphological type of haemangioma, extent of involvement and the treatment indications. Hogeling et al., based on their randomized controlled trial (RCT), suggest a treatment course of at least 6 months which could be modified according to the morphological subtypes, for example deep and mixed IH may continue to proliferate up to 1 year of age and hence, treatment may be extended up to this period.[35] The mean duration of treatment varies from 6 to 10 months. In a recent study on the propranolol treatment in complicated IH, the authors have used the drug for a mean duration of 10.7 months. In the deep and mixed type haemangiomas, they continued the treatment until the age of 12-16 months, in ulcerated lesions up to 9-12 months and in deep peri-orbital and airway lesions up to 15-18 months of age.[31] Marqueling et al. in their meta analysis of 1264 children in 41 studies found that the propranolol was administered for an average duration of 6.4 months (range, 1 weeks to 15 months).[27]"}